The convergence of several new technologies, such as 5G, artificial intelligence (AI), the industrial internet of things (IIoT), autonomous vehicles, and hyperscale computing have brought about a wave of unprecedented innovation. At the same time, these technologies have also pushed electronic design toward a higher level of integration and facilitated the development of diverse vertical…

The healthcare industry is currently undergoing a radical transformation. Patients increasingly have access to better, more personalized treatment options targeting previously intractable illnesses, allowing them to live longer, more fulfilling lives. Yet for Novartis, this hard work is just the beginning of the long journey. While the global healthcare ecosystem continues to flourish, reaching ever…

Taiwan’s three Science-based Industrial Parks – the Hsinchu Science Park in northern Taiwan, Central Taiwan Science Park centered in Taichung, and Southern Taiwan Science Park centered in Tainan – have provided a nurturing base of operations for the country’s high-tech industries. The advantages of locating within a science park include: One-stop Service. Companies need to…

Since the first park opened in Hsinchu in 1980, the emphasis has been on accommodating manufacturers of technology hardware products. That focus is expected to start changing, as Taiwan’s industrial upgrading puts more stress on software, the internet of things, artificial intelligence, and robotics. Over the decades, much of Taiwan’s success as a global manufacturing…

In addition to the New Southbound Policy, one of the central initiatives of the Tsai Ing-wen administration has been the “5+2 Innovative Industry” program focusing on cutting edge industrial sectors. The goal of forging links between those two policies was assigned to the Ministry of Economic Affairs as one of the five flagship projects under…

The Novartis motto – “Reimagining Medicine” – goes to the heart of the company’s deep commitment to developing innovative drugs to help fill the unmet needs of patients worldwide. The Swiss-based pharmaceutical multinational consistently ranks among the top companies investing in R&D, ensuring a constant pipeline of new and groundbreaking treatments. In 2017 the investment…